Injectable peptide rapidly reduces intracranial pressure
15 March 2023
A study for idiopathic intercranial hypertension is the first to show rapid and a major reduction in brain pressure and monthly headaches.
Gut microbiome linked to cancer CAR T therapy response
15 March 2023
For patients with B cell lymphomas, the gut microbiome may modulate the efficacy of CAR-T immunotherapy, research has found.
Enhancing bioavailability in ocular drug delivery
14 March 2023
Innovative technologies were identified as potential solutions for enhancing bioavailability in ocular drug delivery in a research review.
Ministry of Health: the situation with permits for drug trials is coming back to normal
14 March 2023
After a plunge, the number of permits issued for drug trials in Russia is leveling out. According to Sergey Glagolev, Deputy Head of the Ministry, the decrease in the number of permits issued for international multicenter clinical trials was compensated by the growth of local trials.
Could default eligibility improve clinical trial enrolment?
13 March 2023
The number of potential clinical trial participants increased from over 51,000 to 1.7 million after researchers applied a new approach to improve eligibility.
13 March 2023
Rospotrebnadzor has instructed regional authorities of the Russian Federation to conduct immunization against diphtheria in a timely manner. The document with the recommendations of the chief sanitary doctor of the Russian Federation is published on the official portal of regulatory legal acts.
The government will allocate 21.4 billion rubles to support backbone enterprises
10 March 2023
The Prime Minister of the Russian Federation Mikhail Mishustin ordered to allocate 21.4 billion rubles to backbone enterprises of industry and trade in 2023. The document was published on the website of the Government of the Russian Federation.
Russian scientists are developing an anti-cancer drug with hogweed extract
10 March 2023
Scientists of N. P. Ogarev Mordovian State University have derived nanoparticles containing Sosnowsky’s hogweed extract, which in the future can become the basis for the creation of antitumor drugs. It is assumed that the product will be useful in the therapy of superficial malignant skin tumors (basal cell carcinoma and melanoma), bowel cancer and bladder cancer, Gazeta.Ru reports.
EMA’s human medicines committee (CHMP) meeting highlights – February 2023
10 March 2023
In its latest meeting, the Committee for Medicinal Products for Human Use (CHMP) recommended eight new medicines for approval, including an enzyme replacement therapy for a rare disease.
Alzheimer's meds are here. But for the Down syndrome community, it's still the 1980s
09 March 2023
Thirty years ago, the Down syndrome community helped scientists uncover critical learnings about the genetic basis of Alzheimer’s disease. Now, in 2023, we stand on the cusp of new treatments reaching the market, and yet this population has never been included in the clinical research that has underpinned regulatory approvals for these medicines.
NovaMedica will produce migraine drug Relonova in Moscow
23 March 2023
A resource for anti-tumor drugs testing has been launched in Russia
23 March 2023
Building a Community of Trust in Epilepsy & Rare Syndromes
23 March 2023
22 March 2023